Genocea Biosciences Inc ROCE
What is the ROCE of Genocea Biosciences Inc?
The ROCE of Genocea Biosciences Inc is -175.11%
What is the definition of ROCE?
Return on capital employed (ROCE) is a financial ratio that measures a company’s profitability and the efficiency with which its capital is used.
= EBIT / (assets - current liabilities)
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE of companies in the Health Care sector on NASDAQ compared to Genocea Biosciences Inc
What does Genocea Biosciences Inc do?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Companies with roce similar to Genocea Biosciences Inc
- UrbanGold Minerals has ROCE of -176.34%
- Elys Game Technology has ROCE of -176.22%
- Biohaven Ltd has ROCE of -175.96%
- Asiamet Resources has ROCE of -175.74%
- Elsight has ROCE of -175.70%
- Capricor Therapeutics Inc has ROCE of -175.51%
- Genocea Biosciences Inc has ROCE of -175.11%
- Sanibel Ventures has ROCE of -175.10%
- Workhorse Inc has ROCE of -174.48%
- Greenwich LifeSciences has ROCE of -173.92%
- Lordstown Motors has ROCE of -173.29%
- Satsuma Pharmaceuticals has ROCE of -172.20%
- Oncopeptides AB (publ) has ROCE of -172.14%